Dear Neil and HIFA colleagues,
On behalf of Open Pharma and Oxford PharmaGenesis, we are delighted to be part of this important conversation.
Although pharma companies fund approximately half of all biomedical research, access to a substantial amount of this biomedical research is restricted by journal paywalls. Open access publishing ensures that the highest quality peer-reviewed evidence is available to anyone who needs it, anywhere in the world. This has the potential to improve transparency, advance medical science and, we believe, improve patient care. Our position statement on open access ultimately advocates for all research to be made free to read and reuse from the date of publication.
We are looking forward to exploring healthcare professionals' perspectives and experiences of open access publishing!
Many thanks and best wishes,
Joanna
Joanna Donnelly PhD
Communications Consultant
Oxford PharmaGenesis Ltd
UK Tel: +44 1865 390144
joanna.donnelly@pharmagenesis.com
Oxford PharmaGenesis Ltd is registered in England and Wales, registration number 03488862. Our registered office is at Tubney Warren Barn, Tubney, Oxford, OX13 5QJ, UK. This message and any attachments are confidential and the information may be used only for the purpose for which it has been sent. If this message has been sent to you in error, please contact the sender as soon as possible.
Please consider the environment before printing this e-mail
HIFA profile: Joanna Donnelly DPhil is a Communications Consultant at Oxford PharmaGenesis and leads the open access working group and AI discussion forum at Open Pharma, a multi-sponsor collaboration facilitated by Oxford PharmaGenesis seeking to drive transparency in the communication of pharma-sponsored research. She is a member of the HIFA Open Access working group. https://www.hifa.org/support/members/joanna joanna.donnelly AT pharmagenesis.com